Product
MMR
1 clinical trial
1 indication
Indication
PoliomyelitisClinical trial
Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of sIPV Co-administered With MMR and HepA-I.Status: Not yet recruiting, Estimated PCD: 2025-02-10